Journal ArticleOPEN ACCESS

Targeting cancer’s sweet spot: UGP2 as a therapeutic vulnerability

Molecular and Cellular Oncology (2021) 8(6)
DOI: 10.1080/23723556.2021.1990676
11Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Understanding the mechanisms governing metabolic reprogramming that underlie potential vulnerabilities in cancer cells is key to developing novel therapeutic strategies. The catalytic enzyme UDP-glucose pyrophosphorylase 2 (UGP2) drives the production of UDP-glucose. Our recent work demonstrated the crucial role of UGP2 in cancer growth and its regulation of cellular metabolic processes.

Author supplied keywords

Cite

CITATION STYLE

APA

Kim, S., Wolfe, A., & Kim, S. E. (2021). Targeting cancer’s sweet spot: UGP2 as a therapeutic vulnerability. Molecular and Cellular Oncology, 8(6). https://doi.org/10.1080/23723556.2021.1990676

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free